January 12, 2020
Ibex is seeking a partnership for its anti-CD147 (also known as Basigin, EMMPRIN, Neurothelin), with target indications that include cancer, immune disorders, and infectious diseases (particularly COVID-19 and malaria). CD147 has also been reported to be a alternative receptor for infection by coronavirus,1,2 and malaria.3 Targeting of host receptor rather than the pathogen antigen avoids issues concerning pathogen mutations that can decrease treatment or vaccine efficacy. In addition, a clinical trial using a humanized anti-CD147 antibody has been reported to benefit COVID-19 patients4 and other studies point to the safety of anti-CD147 antibodies. Beyond COVID-19, many cancers upregulate CD147, and the protein is thus an excellent target for strategies that include naked antibody and antibody-drug conjugates (ADC). Our approach uses camelid-derived antibodies (VhH), which are simpler and less expensive to produce, are more stable than conventional antibodies. Furthermore, our antibodies can be easily engineered into new formats for alternate therapeutic modalities such as nasal or other inhalation-based therapeutics. We have characterized and demonstrated activity of our anti-CD147 camelid antibodies in naked and ADC formats. We also have camelid antibodies to macrophage migration inhibitory factor (MIF) with demonstrated activity in an animal model of cancer. Ibex is actively seeking partners for commercialization of these assets. Sources: 1. Wang, K., Chen, W., Zhang, Z. et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Sig Transduct Target Ther 5, 283 (2020). 2. Learn more about CD147 – Spike interaction here: 3. Crosnier, C. et al. BASIGIN is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480, 534 (2011). 4. Bian, H., Zheng, Z,H. et al. Meplazumab treats COVID-19 pneumonia: an open-labeled, concurrent controlled add-on clinical trial. medRxiv 2020.03.21.20040691.
December 31, 2020
Ibex announces completion of Phase 1 SBIR Grant
Ibex Biosciences has successfully delivered upon the aims of its anti-MIF SBIR Phase 1 Grant Award. Ibex reported its results and looks forward to filing its phase 2 SBIR
October 9, 2019
Ibex announces publication of FILAMIN-A patent pending
The disclosure teaches antibodies that are useful, inter alia, in methods for detecting and treating human cancer. In a particular aspect, the disclosure teaches novel antibodies that are useful for detecting and treating human breast cancer. In some embodiments, the disclosure teaches novel antibodies that bind to filamin A. In some embodiments, the antibodies are intrabodies.
August 8, 2019
Ibex announces publication of PCBP1 patent pending
The present disclosure provides compositions and methods of using gene therapy to decrease cell migration and metastasis and reduce tumor mass or burden. The methods disclosed herein employ plasmids, vectors, and non-viral vectors that contain PCBP1 and/or PCBP1 mutants which inhibit the expression of cancer biomarkers and decrease cell migration or tumor size.
September 20, 2017
Ibex announces SBIR award
Ibex Biosciences will continue to develop anti-MIF VHH antibodies by establishing larger production levels of the VHH and testing them in animal models. Our work will start with construction and expression of anti-MIF VHH and VHH-Fc antibodies. Succeeding feasibility work will focus on their characterization and demonstration of their functional antibody binding in cell line and animal models. While MIF has been demonstrated to play significant roles in many oncologic conditions, this evaluation will focus on prostate cancer for initial proof of concept. Subsequent development efforts will expand to other solid tumors such as pancreatic, lung, and others.